Effect of SLCO1B1 genotypes on statin intolerance and response to statins

26 August 2022 (08:00 - 19:30)

Organised by:

Sign in to view the resources

Sign in for access options

About the speakers

Mrs Laura Davis

Harefield Hospital, Harefield (United Kingdom of Great Britain & Northern Ireland)

Doctor Tina Zubaida Khan

Harefield Hospital, Harefield (United Kingdom of Great Britain & Northern Ireland)

6 More presentations in this session

Presentation thumbnail

Effect on cholesterol remnants and residual lipid risk with PCSK9 inhibitors: the LIPID-REAL Registry

Doctor A. Cordero (Alicante, ES)

Abstract Slides

Presentation thumbnail

Simulation study on LDL cholesterol target attainment, ASCVD events, and treatment cost of bempedoic acid in a representative German cohort of high- and very-high-CV risk patients

Doctor J. Katzmann (Leipzig, DE)

Abstract Slides

Presentation thumbnail

Persistence to long-term PCSK9 inhibitors treatment and its effectiveness in familial hypercholesterolemia: data from the SAFEHEART study

Doctor R. Alonso (Santiago, CL)

Abstract Slides

Presentation thumbnail

LDL-C goal achievement and lipid-lowering therapy in patients by atherosclerotic cardiovascular disease subtype: the SANTORINI study

Professor K. Ray (London, GB)

Abstract Slides

Presentation thumbnail

Trends in management of cardiovascular risk factors in young adults who go on to develop coronary artery disease

Doctor D. Vikulova (Vancouver, CA)

Abstract Slides

Access the full session

Session thumbnail

Lipids - Drug therapy 2

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022

You may be interested in

Webinar

Unmet needs in lipid management: treatment goals and how to achieve them

Webinar

Risk assessment and lipid management in primary prevention

Webinar

New trial evidence in the field of lipid management

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources